Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: ISIS-113715, Isis.

Gang Liu1

  • 1Abbott Laboratories, R4MC, AP10, 100 Abbott Park Road, Abbott Park, IL 6006-6098, USA. gang.liu@abbott.com

Current Opinion in Molecular Therapeutics
|July 22, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Effects of Pa-pex 11 gene on penicillin production in Penicillium aurantiogriseum].

Wei sheng wu xue bao = Acta microbiologica Sinica·2010
Same author

Danggui-Shaoyao-San and its active fraction JD-30 improve Abeta-induced spatial recognition deficits in mice.

Journal of ethnopharmacology·2010
Same author

Inhibition of lung fluid clearance and epithelial Na+ channels by chlorine, hypochlorous acid, and chloramines.

The Journal of biological chemistry·2010
Same author

Discovery and optimization of novel 3-piperazinylcoumarin antagonist of chemokine-like factor 1 with oral antiasthma activity in mice.

Journal of medicinal chemistry·2010
Same author

Evidence for dimeric BACE-mediated APP processing.

Biochemical and biophysical research communications·2010
Same author

Involvement of mineralocorticoid receptor in high glucose-induced big mitogen-activated protein kinase 1 activation and mesangial cell proliferation.

Journal of hypertension·2010
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Isis is developing ISIS-113715, an antisense inhibitor targeting the PTP1B gene, for treating type 2 diabetes and obesity. This novel therapeutic is currently in phase II clinical trials.

Area of Science:

  • Pharmacology
  • Genetics
  • Metabolic Diseases

Background:

  • Type 2 diabetes and obesity are significant global health challenges.
  • Protein tyrosine phosphatase 1B (PTP1B) is a key regulator of insulin signaling and energy balance.
  • Dysregulation of PTP1B is implicated in the pathogenesis of type 2 diabetes and obesity.

Purpose of the Study:

  • To evaluate the safety and efficacy of ISIS-113715, an antisense inhibitor of PTP1B.
  • To assess the potential of ISIS-113715 as a novel therapeutic for type 2 diabetes and obesity.

Main Methods:

  • ISIS-113715 is an antisense oligonucleotide designed to inhibit PTP1B gene expression.
  • The drug is currently undergoing phase II clinical trials.

Main Results:

Related Experiment Videos

  • Clinical trial data is pending.

Conclusions:

  • ISIS-113715 represents a promising new approach for managing type 2 diabetes and obesity.
  • Further clinical investigation is required to establish its therapeutic value.